Table 1.
Ent ry | Sequence | Ka × 106 M−1 | −ΔH kcal/mol | −ΔS eu | −ΔG kcal/mol | Binding order | |
---|---|---|---|---|---|---|---|
1b | PNA3 | NH2-CTCCTC | 84 ± 80 | 29.4 ± 5.3 | 63 ± 17 | 10.6 ± 0.5 | 1.1 ± 0.2 |
Symmetric sequence, optimal for both parallel triple helix and anti-parallel duplex (strand invasion) | |||||||
2 | D-GPNA1 | NH2-CTD-ArgCCTD-ArgC | 4.6 ± 1.6 | 27.3 ± 2.5 | 61 ± 9 | 9.1 ± 0.2 | 1.8 ± 0.1 |
3 | L-GPNA1 | NH2-CTL-ArgCCTL-ArgC | 2.2 ± 1.6 | 24.2 ± 9.6 | 53 ± 34 | 8.6 ± 0.5 | 2.0 ± 0.1 |
4c | D-GPNA1 | NH2-CTD-ArgCCTD-ArgC | 0.4 | 29.1 | 72 | 7.7 | 2.1 |
5c | L-GPNA1 | NH2-CTL-ArgCCTL-ArgC | 2.5 | 21.0 | 41 | 8.7 | 2.2 |
| |||||||
6b | PNA4 | NH2-CTCTTC | 47 ± 22 | 26.4 ± 3.2 | 54 ± 12 | 10.4 ± 0.3 | 1.3 ± 0.1 |
Sequence optimal for parallel triple helix | |||||||
7 | D-GPNA2 | NH2-CTCTD-ArgTC | 0.5 | 70.0 | 209 | 7.8 | 0.5 |
8 | D-GPNA3 | NH2-CTD-ArgCTTD-ArgC | 0.5 | 41.8 | 114 | 7.8 | 0.8 |
9 | D-GPNA4 | NH2-CTD-ArgCTD-ArgTD-ArgC | 0.6 | 22.9 | 50 | 7.9 | 1.2 |
10 | L-GPNA2 | NH2-CTCTL-ArgTC | 1.8 | 39.6 | 104 | 8.5 | 0.7 |
11 | L-GPNA3 | NH2-CTL-ArgCTTL-ArgC | 0.8 | 58.8 | 170 | 8.0 | 0.5 |
12 | L-GPNA4 | NH2-CTL-ArgCTL-ArgTL-ArgC | 0.5 | 61.6 | 181 | 7.8 | 0.4 |
| |||||||
Sequence optimal for anti-parallel duplex (strand invasion) | |||||||
13d | D-GPNA5 | NH2-CTTD-ArgCTC | 10.5 | 19.8 | 34 | 9.6 | 1.4 |
14d | D-GPNA6 | NH2-CTD-ArgTCTD-ArgC | 5.0 | 13.4 | 14 | 9.1 | 2.0 |
15d | D-GPNA7 | NH2-CTD-ArgTD-ArgCTD-ArgC | 0.4 ±0.01 | 25.8 ± 3.7 | 61 ± 13 | 7.6 ± 0.0 | 2.3 ± 0.0 |
16d | L-GPNA7 | NH2-CTL-ArgTL-ArgCTL-ArgC | 3.8 ± 0.1 | 13.0 ± 7.3 | 14 ± 25 | 8.9 ± 0.3 | 2.1 ± 0.1 |
Average association constants Ka (± standard deviation) in 100 mM sodium acetate, 1.0 mM EDTA, pH 5.5. Entries 1–3 binding to HRP1, entries 4 and 5 binding to DNA version of HRP1 and entries 6–16 binding to HRP2.
From our previous study, reference 10.
Binding to DNA version of HRP1.
PNA is anti-parallel to purine tract of HRP2 (Figure 4B).